Ocugen first patient dosed in Phase 3 registrational trial of OCU410
Ocugen says the first patient has been dosed in its Phase 3 registrational trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.